Pathophysiology of asthma: What has our current understanding taught us about new therapeutic approaches?

Sakula, 1985, Henry Hyde Salter (1823-71): a biographical sketch, Thorax, 40, 887, 10.1136/thx.40.12.887

Holgate, 2011, Asthma: a simple concept but in reality a complex disease, Eur J Clin Invest, 10.1111/j.1365-2362.2011.02534.x

Price, 2011, Leukotriene antagonists as first-line or add-on asthma-controller therapy, N Engl J Med, 364, 1695, 10.1056/NEJMoa1010846

Dahlén, 2011, Asthma treatment guidelines meet the real world, N Engl J Med, 364, 1769, 10.1056/NEJMe1100937

Canonica, 2007, Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) Survey: global adult findings, Allergy, 62, 668, 10.1111/j.1398-9995.2007.01352.x

Akdis, 2011, Mechanisms of allergen-specific immunotherapy, J Allergy Clin Immunol, 127, 18, 10.1016/j.jaci.2010.11.030

Bateman, 2004, Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study, Am J Respir Crit Care Med, 170, 836, 10.1164/rccm.200401-033OC

Bateman, 2008, Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study, Allergy, 63, 932, 10.1111/j.1398-9995.2008.01724.x

Chanez, 2007, Severe asthma in adults: what are the important questions?, J Allergy Clin Immunol, 119, 1337, 10.1016/j.jaci.2006.11.702

Gamble, 2009, The prevalence of nonadherence in difficult asthma, Am J Respir Crit Care Med, 180, 817, 10.1164/rccm.200902-0166OC

Bel, 2005, A rational approach to the management of severe refractory asthma, Treat Respir Med, 4, 365, 10.2165/00151829-200504060-00002

Schwartz, 2002, Intravenous gamma-globulin therapy in bronchial asthma, Allergy Asthma Proc, 23, 15

Di Domenico, 2011, Xolair in asthma therapy: an overview, Inflamm Allergy Drug Targets, 10, 2, 10.2174/187152811794352042

Lowe, 2009, Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma, Br J Clin Pharmacol, 68, 61, 10.1111/j.1365-2125.2009.03401.x

Menzella, 2011, Long-term benefits of omalizumab in a patient with severe non-allergic asthma, Allergy Asthma Clin Immunol, 7, 9, 10.1186/1710-1492-7-9

Smurthwaite, 2002, Local IgE synthesis in allergic rhinitis and asthma, Curr Allergy Asthma Rep, 2, 231, 10.1007/s11882-002-0024-z

Mouthuy, 2011, Presence in sputum of functional dust mite-specific IgE antibodies in intrinsic asthma, Am J Respir Crit Care Med, 10.1164/rccm.201009-1434OC

Busse, 2011, Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children, N Engl J Med, 364, 1005, 10.1056/NEJMoa1009705

Morjaria, 2009, Off-label use of omalizumab in non-asthma conditions: new opportunities, Expert Rev Respir Med, 3, 299, 10.1586/ers.09.11

de Groot, 2010, Comorbidities of asthma during childhood: possibly important, yet poorly studied, Eur Respir J, 36, 671, 10.1183/09031936.00185709

Bisaccioni, 2009, Comorbidities in severe asthma: frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis, Clinics (Sao Paulo), 64, 769, 10.1590/S1807-59322009000800010

Corren, 2008, Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy, J Allergy Clin Immunol, 121, 506, 10.1016/j.jaci.2007.11.026

Lowe, 2011, Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE, Br J Clin Pharmacol, 72, 306, 10.1111/j.1365-2125.2011.03962.x

Pace, 2011, Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics, J Asthma, 48, 387, 10.3109/02770903.2011.561512

Djukanović, 2004, Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma, Am J Respir Crit Care Med, 170, 583, 10.1164/rccm.200312-1651OC

Brusselle, 2009, “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study, Respir Med, 103, 1633, 10.1016/j.rmed.2009.06.014

Prieto, 2006, Effect of omalizumab on adenosine 5’-monophosphate responsiveness in subjects with allergic asthma, Int Arch Allergy Immunol, 139, 122, 10.1159/000090387

Holgate, 2009, The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update, Respir Med, 103, 1098, 10.1016/j.rmed.2009.03.008

Beasley, 2007, Unmet need in inadequately controlled asthma, Respirology, 12, S18, 10.1111/j.1440-1843.2007.01046.x

Rosenwasser, 2003, Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial, J Allergy Clin Immunol, 112, 563, 10.1016/S0091-6749(03)01861-X

Byrd, 2007, Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia, Clin Cancer Res, 13, 4448, 10.1158/1078-0432.CCR-06-1463

Hunt, 2008, Attenuation of IgE affinity for FcepsilonRI radically reduces the allergic response in vitro and in vivo, J Biol Chem, 283, 29882, 10.1074/jbc.M804742200

Holdom, 2011, Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcεRI, Nat Struct Mol Biol, 18, 571, 10.1038/nsmb.2044

Wigginton, 2008, An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotype inhibits basophil degranulation through cross-linking of FcepsilonRI with FcgammaRIIb, Clin Exp Allergy, 38, 313, 10.1111/j.1365-2222.2007.02896.x

Eggel, 2011, Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein, Allergy, 66, 961, 10.1111/j.1398-9995.2011.02546.x

Dal Negro, 2011, Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy, Eur Ann Allergy Clin Immunol, 43, 45

Campbell, 2010, The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective, Allergy, 65, 1141, 10.1111/j.1398-9995.2010.02336.x

Shalev, 2011, Making sense of regulatory T cell suppressive function, Semin Immunol, 10.1016/j.smim.2011.04.003

Robinson, 2010, The role of the T cell in asthma, J Allergy Clin Immunol, 126, 1081, 10.1016/j.jaci.2010.06.025

Strempel, 2010, Phylogenetic and functional analysis identifies Ets-1 as a novel regulator of the Th2 cytokine gene locus, J Immunol, 184, 1309, 10.4049/jimmunol.0804162

Pease, 2011, Targeting chemokine receptors in allergic disease, Biochem J, 434, 11, 10.1042/BJ20101132

Kon, 1998, Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma, Lancet, 352, 1109, 10.1016/S0140-6736(97)12261-9

Fishman-Lobell, 2001, CD4 mAb induced apoptosis of peripheral T cells: multiparameter subpopulation analysis by flow cytometry using attractors, J Immunol Methods, 257, 71, 10.1016/S0022-1759(01)00447-1

Kon, 2001, The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma, Eur Respir J, 18, 45, 10.1183/09031936.01.00064101

Rolland, 2010, Functional regulatory T cells and allergen immunotherapy, Curr Opin Allergy Clin Immunol, 10, 559, 10.1097/ACI.0b013e32833ff2b2

Busse, 2008, Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial, Am J Respir Crit Care Med, 178, 1002, 10.1164/rccm.200708-1200OC

Rech, 2009, Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells, Ann N Y Acad Sci, 1174, 99, 10.1111/j.1749-6632.2009.04939.x

Panina-Bordignon, 2001, The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics, J Clin Invest, 107, 1357, 10.1172/JCI12655

Vijayanand, 2010, Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients, J Immunol, 184, 4568, 10.4049/jimmunol.0901342

Reyes, 2009, 21-23 September 2009, Washington, DC, USA, IDrugs, 12, 692

Antoniu, 2010, Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma, Curr Opin Mol Ther, 12, 770

Yano, 2007, Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome, Clin Cancer Res, 13, 6494, 10.1158/1078-0432.CCR-07-1324

Bellou, 2005, Costimulation: critical pathways in the immunologic regulation of asthma, Curr Allergy Asthma Rep, 5, 149, 10.1007/s11882-005-0089-6

Schiff, 2011, Abatacept treatment for rheumatoid arthritis, Rheumatology (Oxford), 50, 437, 10.1093/rheumatology/keq287

Jaffar, 1999, Essential role for both CD80 and CD86 costimulation, but not CD40 interactions, in allergen-induced Th2 cytokine production from asthmatic bronchial tissue: role for alphabeta, but not gammadelta, T cells, J Immunol, 163, 6283, 10.4049/jimmunol.163.11.6283

Hidi, 2000, Role of B7-CD28/CTLA-4 costimulation and NF-kappa B in allergen-induced T cell chemotaxis by IL-16 and RANTES, J Immunol, 164, 412, 10.4049/jimmunol.164.1.412

Lordan, 2001, The role of CD28-B7 costimulation in allergen-induced cytokine release by bronchial mucosa from patients with moderately severe asthma, J Allergy Clin Immunol, 108, 976, 10.1067/mai.2001.119740

Liu, 2007, Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation, J Allergy Clin Immunol, 120, 238, 10.1016/j.jaci.2007.06.004

Siddiqui, 2010, Airway wall expression of OX40/OX40L and interleukin-4 in asthma, Chest, 137, 797, 10.1378/chest.09-1839

Oh, 2010, Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma, Eur Respir Rev, 19, 46, 10.1183/09059180.00007609

Jiang, 2000, IL-4/IL-13 signaling beyond JAK/STAT, J Allergy Clin Immunol, 105, 1063, 10.1067/mai.2000.107604

Bottema, 2010, Interleukin 13 and interleukin 4 receptor-α polymorphisms in rhinitis and asthma, Int Arch Allergy Immunol, 153, 259, 10.1159/000314366

Borish, 1999, Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial, Am J Respir Crit Care Med, 160, 1816, 10.1164/ajrccm.160.6.9808146

Borish, 2001, IL-4R Asthma Study Group. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma, J Allergy Clin Immunol, 107, 963, 10.1067/mai.2001.115624

Hart, 2002, Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma, Clin Exp Immunol, 130, 93, 10.1046/j.1365-2249.2002.01973.x

Gauvreau, 2011, Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma, Am J Respir Crit Care Med, 183, 1007, 10.1164/rccm.201008-1210OC

Cockcroft, 1987, Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine, J Allergy Clin Immunol, 79, 734, 10.1016/0091-6749(87)90204-1

Oh, 2010, An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males, Br J Clin Pharmacol, 69, 645, 10.1111/j.1365-2125.2010.03647.x

Shanafelt, 1998, An immune cell-selective interleukin 4 agonist, Proc Natl Acad Sci U S A, 95, 9454, 10.1073/pnas.95.16.9454

Burmeister Getz, 2009, Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma, J Clin Pharmacol, 49, 1025, 10.1177/0091270009341183

Wenzel, 2007, Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies, Lancet, 370, 1422, 10.1016/S0140-6736(07)61600-6

Slager, 2010, IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist, J Allergy Clin Immunol, 126, 875, 10.1016/j.jaci.2010.08.001

Prakash, 2008, Comparing in vitro and in vivo activity of 2’-O-[2-(methylamino)-2-oxoethyl]- and 2’-O-methoxyethyl-modified antisense oligonucleotides, J Med Chem, 51, 2766, 10.1021/jm701537z

Kakkar, 2011, Population PK and IgE Pharmacodynamic analysis of a fully human monoclonal antibody against IL-4 receptor, Pharm Res, 10.1007/s11095-011-0481-y

Corren, 2010, A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma, Am J Respir Crit Care Med, 181, 788, 10.1164/rccm.200909-1448OC

Foster, 2002, Interleukin-5 and eosinophils as therapeutic targets for asthma, Trends Mol Med, 8, 162, 10.1016/S1471-4914(02)02302-X

Hargreave, 2007, Quantitative sputum cell counts as a marker of airway inflammation in clinical practice, Curr Opin Allergy Clin Immunol, 7, 102, 10.1097/ACI.0b013e328013e3c2

Leckie, 2000, Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response, Lancet, 356, 2144, 10.1016/S0140-6736(00)03496-6

Flood-Page, 2007, A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma, Am J Respir Crit Care Med, 176, 1062, 10.1164/rccm.200701-085OC

Flood-Page, 2003, Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway, Am J Respir Crit Care Med, 167, 199, 10.1164/rccm.200208-789OC

Menzies-Gow, 2003, Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics, J Allergy Clin Immunol, 111, 714, 10.1067/mai.2003.1382

Liu, 2002, Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge, J Immunol, 169, 6452, 10.4049/jimmunol.169.11.6452

Flood-Page, 2003, Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics, J Clin Invest, 112, 1029, 10.1172/JCI17974

Nair, 2009, Mepolizumab for prednisone-dependent asthma with sputum eosinophilia, N Engl J Med, 360, 985, 10.1056/NEJMoa0805435

Haldar, 2009, Mepolizumab and exacerbations of refractory eosinophilic asthma, N Engl J Med, 360, 973, 10.1056/NEJMoa0808991

Kim, 2010, Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome, J Allergy Clin Immunol, 125, 1336, 10.1016/j.jaci.2010.03.028

Busse, 2010, A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma, J Allergy Clin Immunol, 125, 803, 10.1016/j.jaci.2009.11.048

Kips, 2003, Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study, Am J Respir Crit Care Med, 167, 1655, 10.1164/rccm.200206-525OC

Busse, 2010, Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma, J Allergy Clin Immunol, 125, 1237, 10.1016/j.jaci.2010.04.005

Oh, 2011, Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma, Inflamm Allergy Drug Targets, 10, 180, 10.2174/187152811795564073

Doe, 2010, Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD, Chest, 138, 1140, 10.1378/chest.09-3058

Durrant, 2010, Emerging roles of T helper subsets in the pathogenesis of asthma, Immunol Invest, 39, 526, 10.3109/08820131003615498

Parker, 2011, Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma, BMC Pulm Med, 11, 14, 10.1186/1471-2466-11-14

Roussel, 2010, IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation, J Immunol, 184, 4531, 10.4049/jimmunol.0903162

Howarth, 2005, Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma, Thorax, 60, 1012, 10.1136/thx.2005.045260

Berry, 2006, Evidence of a role of tumor necrosis factor alpha in refractory asthma, N Engl J Med, 354, 697, 10.1056/NEJMoa050580

Morjaria, 2008, The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind randomised placebo-controlled trial, Thorax, 63, 584, 10.1136/thx.2007.086314

Holgate, 2011, Efficacy/safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial, Eur Respir J, 37, 1352, 10.1183/09031936.00063510

Erin, 2006, The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma, Am J Respir Crit Care Med, 174, 753, 10.1164/rccm.200601-072OC

Wenzel, 2009, A randomized, double-blind, placebo-controlled study of tumor necrosis factor alpha blockade in severe persistent asthma, Am J Respir Crit Care Med, 179, 549, 10.1164/rccm.200809-1512OC

Holgate, 2010, A look at the pathogenesis of asthma: the need for a change in direction, Discov Med, 9, 439

Holgate, 2009, A new look at the pathogenesis of asthma, Clin Sci (Lond), 118, 439, 10.1042/CS20090474

Shirtcliffe, 2011, The multiple dimensions of airways disease: targeting treatment to clinical phenotypes, Curr Opin Pulm Med, 17, 72, 10.1097/MCP.0b013e328341f181

Morjaria, 2011, Stratified medicine in selecting biologics for the treatment of severe asthma, Curr Opin Allergy Clin Immunol, 11, 58, 10.1097/ACI.0b013e3283423245

Saha, 2008, Increased sputum and bronchial biopsy IL-13 expression in severe asthma, J Allergy Clin Immunol, 121, 685, 10.1016/j.jaci.2008.01.005

Park, 2005, Interleukin-13 and interleukin-5 in induced sputum of eosinophilic bronchitis: comparison with asthma, Chest, 128, 1921, 10.1016/S0012-3692(15)52584-1

Berry, 2004, Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis, J Allergy Clin Immunol, 114, 1106, 10.1016/j.jaci.2004.08.032

Woodruff, 2009, T-helper type 2-driven inflammation defines major subphenotypes of asthma, Am J Respir Crit Care Med, 180, 388, 10.1164/rccm.200903-0392OC

Dougherty, 2010, Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma, J Allergy Clin Immunol, 125, 1046, 10.1016/j.jaci.2010.03.003

Choy, 2011, Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways, J Immunol, 186, 1861, 10.4049/jimmunol.1002568

Silvestri, 2006, High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: markers of systemic inflammation?, Clin Exp Allergy, 36, 1373, 10.1111/j.1365-2222.2006.02502.x

Baines, 2010, Differential gene expression and cytokine production from neutrophils in asthma phenotypes, Eur Respir J, 35, 522, 10.1183/09031936.00027409

Baines, 2011, Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples, J Allergy Clin Immunol, 127, 153, 10.1016/j.jaci.2010.10.024

Scharschmidt, 2009, Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens, J Allergy Clin Immunol, 124, 496, 10.1016/j.jaci.2009.06.046

Groschwitz, 2009, Intestinal barrier function: molecular regulation and disease pathogenesis, J Allergy Clin Immunol, 124, 3, 10.1016/j.jaci.2009.05.038

Tieu, 2010, Evidence for diminished levels of epithelial psoriasin and calprotectin in chronic rhinosinusitis, J Allergy Clin Immunol, 125, 667, 10.1016/j.jaci.2009.11.045

Holgate, 2007, Epithelium dysfunction in asthma, J Allergy Clin Immunol, 120, 1233, 10.1016/j.jaci.2007.10.025

de Boer, 2008, Altered expression of epithelial junctional proteins in atopic asthma: possible role in inflammation, Can J Physiol Pharmacol, 86, 105, 10.1139/Y08-004

Stevens, 2008, Dysregulated repair in asthmatic paediatric airway epithelial cells: the role of plasminogen activator inhibitor-1, Clin Exp Allergy, 38, 1901, 10.1111/j.1365-2222.2008.03093.x

Grainge, 2011, Effect of bronchoconstriction on airway remodeling in asthma, N Engl J Med, 364, 2006, 10.1056/NEJMoa1014350

Hilty, 2010, Disordered microbial communities in asthmatic airways, PLoS One, 5, e8578, 10.1371/journal.pone.0008578

Lin, 2011, Emerging pathways in asthma: Innate and adaptive interactions, Biochim Biophys Acta, 10.1016/j.bbagen.2011.04.015

Papadopoulos, 2011, Viruses and bacteria in acute asthma exacerbations—a GA2LEN-DARE systematic review, Allergy, 66, 458, 10.1111/j.1398-9995.2010.02505.x

Jackson, 2008, Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children, Am J Respir Crit Care Med, 178, 667, 10.1164/rccm.200802-309OC

Holt, 2011, Interaction between adaptive and innate immune pathways in the pathogenesis of atopic asthma: operation of a lung/bone marrow axis, Chest, 139, 1165, 10.1378/chest.10-2397

Wark, 2005, Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus, J Exp Med, 201, 937, 10.1084/jem.20041901

Brandelius, 2011, dsRNA-induced expression of thymic stromal lymphopoietin (TSLP) in asthmatic epithelial cells is inhibited by a small airway relaxant, Pulm Pharmacol Ther, 24, 59, 10.1016/j.pupt.2010.10.004

Bosco, 2010, Decreased activation of inflammatory networks during acute asthma exacerbations is associated with chronic airflow obstruction, Mucosal Immunol, 3, 399, 10.1038/mi.2010.13

Jartti, 2010, Allergic sensitization is associated with rhinovirus-, but not other virus-, induced wheezing in children, Pediatr Allergy Immunol, 21, 1008, 10.1111/j.1399-3038.2010.01059.x

Jartti, 2011, Rhinovirus-induced bronchiolitis and asthma development, Pediatr Allergy Immunol, 22, 350, 10.1111/j.1399-3038.2011.01170.x

Whitsett, 2006, Transcriptional regulation of perinatal lung maturation, Pediatr Clin North Am, 53, 873, 10.1016/j.pcl.2006.08.009

Chen, 2010, Foxa2 programs Th2 cell-mediated innate immunity in the developing lung, J Immunol, 184, 6133, 10.4049/jimmunol.1000223

Maeda, 2011, Airway epithelial transcription factor NKX2-1 inhibits mucous cell metaplasia and Th2 inflammation, Am J Respir Crit Care Med, 10.1164/rccm.201101-0106OC